Dermatology

Inactive occupational status and low educational level were associated with pain, late disease onset, and greater number of affected areas in patients with hidradenitis suppurativa.

Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected by hidradenitis suppurativa (HS), spoke on misconceptions she’s encountered on her HS disease journey and the importance for physicians to be conscientious of their advice to patients.

A case report of a patient with acne fulminans, a rare form of acne vulgaris, discussed the clinical manifestations of the disease, physical examination findings, and management strategies.

Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with hidradenitis suppurativa (HS), spoke on key areas of HS comprehension and management that warrant further investigation in clinical research.

Treatment with anti-interleukin (IL)-17A inhibitors for psoriasis consistently improved outcomes across primary and secondary endpoints compared with all other approved biologics, and researchers also found differences between anti-IL-17A inhibitors.

Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with hidradenitis suppurativa (HS), discussed step edits and other barriers to treatment caused by insurance requirements in the management of HS.

Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with hidradenitis suppurativa (HS), spoke on the need for awareness among physicians and patients on the clinical features of HS in regard to both physical and psychosocial burdens.

A review explores critical factors for dermatologists to consider in managing the physical and behavioral care needs of LGBTQIA patients with hidradenitis suppurativa.

The journey to a diagnosis of hidradenitis suppurativa was different for her compared with the path faced by her children, said Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with the disease.

An increased risk of developing myocardial infarction was observed among patients with hidradenitis suppurativa (HS), whereas risk of cerebrovascular accident and peripheral vascular disease was comparable between those with HS and controls.

Ruxolitinib (Opzelura) cream is the first and only FDA-approved treatment for repigmentation in patients with vitiligo.

Over half of the patients (53%) included in the study indicated that frontal fibrosing alopecia had a negative impact on their health-related quality of life (HRQOL).

Many algorithms claiming to identify melanoma better than dermatologists are trained on retrospective datasets, which is not reflective of real-world clinical practice, said Jonathan Kentley, MBBS, MSc, research fellow at Memorial Sloan Kettering Cancer Center.

The risk of wound-related issues was approximately 2-fold in adult patients with hidradenitis suppurativa (HS) undergoing total hip/knee arthroplasty vs those without HS.

Individuals tend to be more affected by vitiligo if it is visible on their face or hands, said David Rosmarin, MD, vice chair of research and education, Department of Dermatology, Tufts Medical Center.

Of 10 patient-reported outcome measures studied, only 2 received an ‘A’ rating for sufficient content validity and internal structure.

Jonathan Kentley, MBBS, MSc, research fellow at Memorial Sloan Kettering Cancer Center, talks about how dermatologists are working with artificial intelligence (AI) while still making sure patient voices are heard.

Combined oral contraceptives (COCs) and, more recently, spironolactone, have been identified as options for adolescent females with acne and hidradenitis suppurativa (HS), although varying levels of data are available supporting their use in these patients.

We need more educational or clinical projects that have a real-world impact on reducing disparities in dermatology, said Art Papier, MD, dermatologist, CEO, VisualDx.

According to the researchers of the study, managing patients with hidradenitis suppurativa holistically may help reduce the burden of their disease.

The FDA approved Eli Lilly’s baricitinib drug to regrow hair in patients with alopecia; the American Medical Association (AMA) adopts resolutions that go against criminalization of abortion; an experimental amyotrophic lateral sclerosis (ALS) therapy under review with the FDA has been approved in Canada.

The researchers underscored the importance of the patient voice in the field, as some aspects of treatment can only be assessed through the patient.

The researchers highlighted that the dermatology field is considered one of the least diverse and most competitive specialties.

A recent study found that patient assessments of symptoms are fit for purpose and can be used by adolescents with alopecia areata in clinical trials and practice.

Chargemaster lists may encourage patients to shop around for services, but the authors of this report said the implications of this change for dermatology are not well-defined.

The findings come from a novel longitudinal analysis of 400 patients, which the researchers said validates and further underscores the utility of laboratory parameters for the management of hidradenitis suppurativa.

Hidradenitis suppurativa (HS) was associated with a variety of comorbid conditions, from psoriasis to hypertension.

According to the researchers of this new study, the biomarker may have potential for use with clinical scores in treatment decisions or in clinical trials that focus on hidradenitis suppurativa (HS).

Hilary Baldwin, MD, medical director, Acne Treatment and Research Center, discusses new therapies for acne and unmet needs for the condition.

Within 4 weeks of starting treatment, patients experienced improvements in their condition, indicating an anti-inflammatory effect of the treatment.